Vizimpro patents are set to expire in 2026, opening the possibility for generic versions of the drug.
When Does Vizimpro's Main Patent Expire?
The primary patent for Vizimpro (duodenal-released amlodipine besylate) is listed with an expiration date in 2026 [1]. This patent is crucial for protecting the drug's market exclusivity.
What Happens When Vizimpro's Patent Expires?
Upon patent expiration, other pharmaceutical companies may seek to market generic versions of Vizimpro. Generic drugs are typically bioequivalent to their brand-name counterparts but are offered at a lower cost, which can significantly impact market dynamics and patient access [2].
Can Generic Vizimpro Enter the Market Before Patent Expiry?
Generally, generic entry is anticipated following the expiration of key patents. However, the specific timeline for generic availability can be influenced by various factors, including the outcome of any patent litigation and the regulatory approval process for generic applications [1]. DrugPatentWatch.com tracks these patent statuses and potential entry dates.
Are There Other Patents Protecting Vizimpro?
Beyond the 2026 patent, there may be other patents, including method of use patents or formulation patents, that could extend exclusivity or present challenges for generic manufacturers. Companies often file multiple patents to create a more robust patent thicket around a drug [1].
Who Manufactures Vizimpro?
Vizimpro is manufactured by Takeda Pharmaceutical Company [3]. Takeda is the innovator company that developed and markets the brand-name drug.